qz
Eli Lilly CFO Lucas Montrace explains what drove 56% year-over-year revenue beat

Eli Lilly CFO Lucas Montrace explains what drove 56% year-over-year revenue beat [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 70.08

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]

Match Score: 67.76

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 67.70

Destination
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]

Match Score: 67.70

Destination
Beat Saber support is ending on PS VR and PS VR2

It's the end of the line for Beat Saber on PS VR and PS VR2. While you'll still be able to buy and play the base game on both platforms, as well as any songs and music packs that were releas [...]

Match Score: 59.78

Destination
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]

Match Score: 54.44

venturebeat
CFOs are now getting their own 'vibe coding' moment thanks to Datarails

For the modern CFO, the hardest part of the job often isn't the math—it's the storytelling. After the books are closed and the variances calculated, finance teams spend days, sometimes wee [...]

Match Score: 54.18

Destination
Eli Lilly CEO David Rick’s’ pay rose to nearly $30 million in 2024

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.Read more.. [...]

Match Score: 54.16

Destination
Eli Lilly promises to make new weight-loss pill in the U.S.

Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to [...]

Match Score: 54.16